Jpmorgan Chase & CO Intercept Pharmaceuticals, Inc. Transaction History

Jpmorgan Chase & CO

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$9.99 - $18.71 $2.6 Million - $4.86 Million	259,999 Added 873.3%	289,771 $5.37 Million
Q2 2023 Aug 11, 2023	SELL	$9.17 - $19.29 $1.52 Million - $3.2 Million	-165,696 Reduced 84.77%	29,772 $329,000
Q1 2023 May 18, 2023	BUY	$12.53 - $21.71 $234,737 - $406,715	18,734 Added 10.6%	195,468 $2.63 Million
Q1 2023 May 11, 2023	SELL	$12.53 - $21.71 $2.76 Million - $4.78 Million	-220,069 Reduced 55.46%	176,734 $2.37 Million
Q4 2022 Feb 13, 2023	BUY	$11.61 - $16.11 $2.59 Million - $3.59 Million	222,952 Added 128.24%	396,803 $4.91 Million

Q3 2022 Nov 14, 2022	SELL	$12.21 - $19.7 $1.85 Million - $2.98 Million	-151,129 Reduced 46.5%	173,851 $2.43 Million
Q2 2022 Aug 11, 2022	BUY	$11.23 - $19.59 $219,422 - $382,769	19,539 Added 6.4%	324,980 $4.49 Million
Q1 2022 May 11, 2022	BUY	$13.37 - $17.79 $1.63 Million - $2.17 Million	121,955 Added 66.47%	305,441 $4.97 Million
Q4 2021 Feb 10, 2022	SELL	$14.28 - $19.53 $211,715 - $289,551	-14,826 Reduced 7.48%	183,486 $2.99 Million
Q3 2021 Nov 12, 2021	BUY	$12.99 - $20.47 $2.58 Million - $4.06 Million	198,312 New	198,312 $2.94 Million

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.